Tyrvaya vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Tyrvaya | US Miebo | |
|---|---|---|
| Generic name | varenicline nasal spray | perfluorohexyloctane |
| Drug class | Nicotinic Acetylcholine Receptor Agonist (Nasal) | Semifluorinated Alkane (Eye Drop) |
| Treats | Dry eye disease | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Viatris | Bausch + Lomb |
| Year approved | 2021 | 2023 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | — | — |
| Common side effects | Sneezing, Cough, Throat irritation, Nose irritation | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Tyrvaya or Miebo better?
Neither is universally "better." Tyrvaya (varenicline nasal spray) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Tyrvaya and Miebo?
Tyrvaya is a Nicotinic Acetylcholine Receptor Agonist (Nasal) made by Viatris, while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Tyrvaya has the larger estimated TV advertising budget of the two.